Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene autoleucel versus rituximab in severe refractory diffuse cutaneous systemic sclerosis
2023-510380-34-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 24
01
Overview
Phase 2, randomised, open-label trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing Rapcabtagene autoleucel arm with Rituximab control arm (2 arms). Primary endpoint: Treatment response by rCRISS50 at Week 52. Planned start Dec 2024; status: authorised.
02
Drugs
rapcabtagene autoleucelrituximab
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on 2023-510380-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510380-34-00.